Alendronate Sodium Tablet
Product Images NDC 71205-048

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 71205-048). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alendronate Fig1)

The text describes a chart or graph that shows the cumulative incidence of hip fractures over a three-year study. The study includes patients who had radiographic vertebral fracture at the beginning of the study. The data compares a placebo group to a group taking alendronate sodium. The x-axis shows time in months and the y-axis shows the percentage of cumulative incidence.*

FDA Label Image

71205-048-04 (Alendronate Fig10)

This is a prescription medication labeled as Alendronate Sodium 70mg in white to off-white, oval shaped, biconvex, uncoated tablets. It is a once-weekly dosage containing 4 tablets. Each tablet contains 91.363 mg of alendronate in sodium USP equivalent to 70 mg alendronic acid. The manufacturer is Aurobindo Pharma Limited Hyderabad-500 038, India. Lot number is 400000 SNEMASTER and it should be stored at 20° to 25°C (68° to 77°F). A medication guide must be dispensed to each patient. No non-English characters were recognized.*

FDA Label Image

Figure 2 (Alendronate Fig2)

This appears to be a table of data related to the increase in bone mineral density in postmenopausal women with osteoporosis who were treated with alendronate at a dosage of 10mg/day for three years. The data shows a mean percentage increase in BMD for the lumbar spine, femoral neck, and trochanter compared to a placebo. The exact numbers are not easily discernible from the provided text.*

FDA Label Image

Figure 3 (Alendronate Fig3)

This is a table displaying the mean percent change from baseline in Bone Mineral Density (BMD) in postmenopausal women with osteoporosis who were treated with Alendronate 10 mg/day compared to placebo. The data shows the time course of the effect of the treatment on the BMD percent change from the baseline, measured at the lumbar spine. The study was a multinational trial and the data was recorded over the course of 36 months.*

FDA Label Image

Figure 4 (Alendronate Fig4)

FDA Label Image

Figure 5 (Alendronate Fig5)

FDA Label Image

Figure 6 (Alendronate Fig6)

The given text seems to be a report on the effect of Alendronate on Serum Alkaline Phosphatase in Paget's Disease of Bone. The text includes a table with mean % change from baseline for Alendronate, Placebo, and Etidronate. The study was conducted on two groups - a multinational group and a US group, with 27 and 41 participants, respectively, over a period of 6 months.*

FDA Label Image

Chemical Structure (Alendronate Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.